Antagonist-induced increase in 5-HT1A-receptor expression in adult rat hippocampus and cortex

Synapse

Volumn 61, Issue 7, 2007, Pages 531-539

  Abbas, Syed Y ^a   Nogueira, Maria I ^a   Azmitia, Efrain C ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Dentate gyrus; Inverse agonist; Morphometric; Serotonin; WAY 100635

Indexed keywords

N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT;

ANIMALS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS;

EID: 34248513038     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20399     Document Type: Article

References (44)

1. Anthony TE, Azmitia EC. 1997. Molecular characterization of antipeptide antibodies against the 5-HT1A receptor: Evidence for state-dependent antibody binding. Brain Res Mol Brain Res 50:277-284.
2. Artigas F, Adell A, Celada P. 2006. Pindolol augmentation of antidepressant response. Curr Drug Targets 7:139-147.
3. Azmitia EC, Rubinstein VJ, Strafaci JA, Rios JC, Whitaker-Azmitia PM. 1995. 5-HT1A agonist and dexamethasone reversal of parachloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. Brain Res 677:181-192.
4. Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM. 1996. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 14:35-46.
5. Barros M, Mello EL, Maior RS, Muller CP, de Souza Silva MA, Carey RJ, Huston JP, Tomaz C. 2003. Anxiolytic-like effects of the selective 5-HT1A receptor antagonist WAY 100635 in nonhuman primates. Eur J Pharmacol 482:197-203.
6. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. 2004. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 9:386-392.
7. Bijak M, Tokarski K, Czyrak A, Mackowiak M, Wedzony K. 1996. Imipramine increases the 5-HT1A receptor-mediated inhibition of hippocampal neurons without changing the 5-HT1A receptor binding. Eur J Pharmacol 305:79-85.
8. Blier P, de Montigny C, Chaput Y. 1990. A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence. J Clin Psychiatry 51 (Suppl):14-20; discussion 21.
9. Burnet PW, Sharp T, LeCorre SM, Harrison PJ. 1999. Expression of 5-HT receptors and the 5-HT transporter in rat brain after electroconvulsive shock. Neurosci Lett 277:79-82.
10. Chang MS, Ariah LM, Marks A, Azmitia EC. 2005. Chronic gliosis induced by loss of S-100B: Knockout mice have enhanced GFAP-immunoreactivity but blunted response to a serotonin challenge. Brain Res 1031:1-9.
11. Clarke C, Clarke K, Muneyyirci J, Azmitia E, Whitaker-Azmitia PM. 1996. Prenatal cocaine delays astroglial maturation: Immunodensitometry shows increased markers of immaturity (vimentin and GAP-43) and decreased proliferation and production of the growth factor S-100. Brain Res Dev Brain Res 91:268-273.
12. Cooper JR, Bloom FE, Roth RH. 1996. The biochemical basis of neuropharmacology, 7th ed. New York: Oxford.
13. Cosi C, Koek W. 2000. The putative [dlt]silent[dmt] 5-HT(1A) receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT(1A) receptors. Eur J Pharmacol 401:9-15.
14. Dawson LA, Nguyen HQ, Smith DL, Schechter LE. 2002. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J Psychopharmacol 16:145-152.
15. Futterer CD, Maurer MH, Schmitt A, Feldmann RE, Jr, Kuschinsky W, Waschke KF. 2004. Alterations in rat brain proteins after desflurane anesthesia. Anesthesiology 100:302-308.
16. Gartside SE, Umbers V, Hajos M, Sharp T. 1995. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: Effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115:1064-1070.
17. Gartside SE, Clifford EM, Cowen PJ, Sharp T. 1999. Effects of (-)-tertatolol, (-)-penbutolol and (±)-pindolol in combination with paroxetine on presynaptic 5-HT function: An in vivo microdialysis and electrophysiological study. Br J Pharmacol 127:145-152.
18. Giovacchini G, Toczek MT, Bonwetsch R, Bagic A, Lang L, Fraser C, Reeves-Tyer P, Herscovitch P, Eckelman WC, Carson RE, Theodore WH. 2005. 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med 46:1128-1135.
19. Hjorth S, Bengtsson HJ, Milano S. 1996. Raphe 5-HT1Aautoreceptors, but not postsynaptic 5-HT1A receptors or β-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo. Eur J Pharmacol 316:43-47.
20. Hsiung SC, Adlersberg M, Arango V, Mann JJ, Tamir H, Liu KP. 2003. Attenuated 5-HT1A receptor signaling in brains of suicide victims: Involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. J Neurochem 87:182-194.
21. Huang J, Azmitia EC. 1999. Homologous regulation of 5-HT1A receptor mRNA in adult rat hippocampal dentate gyrus. Neurosci Lett 270:5-8.
22. Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME. 2006. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci USA 103:702-707.
23. Khawaja X. 1995. Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist. Brain Res 673:217-225.
24. Khawaja XZ, Smith DL, Nawoschik SP, Zhang J, Dunlop J, Dilks DW, Olsen M, Schechter LE. 2006. WAY-100635 antagonist-induced plasticity of 5-HT receptors: Regulatory differences between a stable cell line and an in vivo native system. J Neurochem 98: 134-145.
25. Kinoshita H, Jessop DS, Roberts DJ, Hishida S, Harbuz MS. 2003. Chronic ethanol administration and withdrawal decreases 5-HT1A mRNA, but not 5-HT4 expression in the rat hippocampus. Pharmacol Toxicol 93:100-102.
26. Lai MK, Tsang SW, Francis PT, Esiri MM, Keene J, Hope T, Chen CP. 2003. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res 974:82-87.
27. Le Poul E, Boni C, Hanoun N, Laporte AM, Laaris N, Chauveau J, Hamon M, Lanfumey L. 2000. Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 39:110-122.
28. Malagie I, Trillat AC, Douvier E, Anmella MC, Dessalles MC, Jacquot C, Gardier AM. 1996. Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: An in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 354: 785-790.
29. Meschaks A, Lindstrom P, Halldin C, Farde L, Savic I. 2005. Regional reductions in serotonin 1A receptor binding in juvenile myoclonic epilepsy. Arch Neurol 62:946-950.
30. Milligan G, Kim GD, Mullaney I, Adie EJ. 1995. Regulation of cellular Gs α levels and basal adenylyl cyclase activity by expression of the β2-adrenoceptor in neuroblastoma cell lines. Mol Cell Biochem 149/150:213-216.
31. Newman-Tancredi A, Conte C, Chaput C, Spedding M, Millan MJ. 1997. Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br J Pharmacol 120:737-739.
32. Nishi M, Azmitia EC. 1999. Agonist- and antagonist-induced plasticity of rat 5-HT1A receptor in hippocampal cell culture. Synapse 31:186-195.
33. Palchaudhuri M, Flugge G. 2005. 5-HT1A receptor expression in pyramidal neurons of cortical and limbic brain regions. Cell Tissue Res 321:159-172.
34. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates. New York: Academic Press.
35. Roman V, Walstra I, Luiten PG, Meerlo P. 2005. Too little sleep gradually desensitizes the serotonin 1A receptor system. Sleep 28:1505-1510.
36. Romero L, Hervas I, Artigas F. 1996. The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 219:123-126.
37. Segal M, Azmitia EC, Whitaker-Azmitia PM. 1989. Physiological effects of selective 5-HT1a and 5-HT1b ligands in rat hippocampus: Comparison to 5-HT. Brain Res 502:67-74.
38. Sharp T, Gartside SE, Umbers V. 1997. Effects of co-administration of a monoamine oxidase inhibitor and a 5-HT1A receptor antagonist on 5-hydroxytryptamine cell firing and release. Eur J Pharmacol 320:15-19.
39. Sibug RM, Compaan JC, Meijer OC, Van der Gugten J, Olivier B, De Kloet ER. 1998. Flesinoxan treatment reduces 5-HT1A receptor mRNA in the dentate gyrus independently of high plasma corticosterone levels. Eur J Pharmacol 353:207-214.
40. Steward O, Worley P. 2002. Local synthesis of proteins at synaptic sites on dendrites: Role in synaptic plasticity and memory consolidation? Neurobiol Learn Mem 78:508-527.
41. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G. 1998. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci 18:7394-7401.
42. Welsby PJ, Kellett E, Wilkinson G, Milligan G. 2002. Enhanced detection of receptor constitutive activity in the presence of regulators of G protein signaling: Applications to the detection and analysis of inverse agonists and low-efficacy partial agonists. Mol Pharmacol 61:1211-1221.
43. Ying SW, Abbas SY, Harrison NL, Goldstein PA. 2006. Propofol block of I contributes to the suppression of neuronal excitability and rhythmic burst firing in thalamocortical neurons. Eur J Neurosci 23:465-480.
44. Zhong J, Zhang T, Bloch LM. 2006. Dendritic mRNAs encode diversified functionalities in hippocampal pyramidal neurons. BMC Neurosci 7:17.